Phase II trial of cisplatin and capecitabine in patients with squamous cell carcinoma of the head and neck, and correlative study of angiogenic factors

The combination of cisplatin and capecitabine was evaluated in patients with recurrent or unresectable squamous cell carcinoma of the head and neck (HNSCC), and outcome parameters were correlated with the expression of thymidine phosphorylase (TP), thymidilate syntetase (TS), vascular endothelial gr...

Descripción completa

Detalles Bibliográficos
Autores principales: Hitt, R, Jimeno, A, Rodríguez-Pinilla, M, Rodríguez-Peralto, J L, Millán, J M, López-Martín, A, Brandariz, A, Peña, C, Cortés-Funes, H
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409797/
https://www.ncbi.nlm.nih.gov/pubmed/15597103
http://dx.doi.org/10.1038/sj.bjc.6602275

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409797/
https://www.ncbi.nlm.nih.gov/pubmed/15597103
http://dx.doi.org/10.1038/sj.bjc.6602275

Ejemplares similares